Ascendis Pharma Files 6-K, Incorporates by Reference
Ticker: ASND · Form: 6-K · Filed: Aug 13, 2025 · CIK: 1612042
Sentiment: neutral
Topics: reporting, foreign-private-issuer, securities-registration
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K, incorporating previous S-8 filings. Standard reporting.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on August 13, 2025, to report information as a foreign private issuer. The filing is related to registration statements on Form S-8, specifically referencing registration numbers 333-203040 and 3. The company is incorporated in G7 and its fiscal year ends on December 31.
Why It Matters
This filing indicates ongoing reporting requirements for Ascendis Pharma A/S as a foreign private issuer, potentially related to employee stock plans or other securities offerings.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain new material financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 333-203040 (dollar_amount) — Form S-8 Registration Number
- August 13, 2025 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, have filed or are required to file with a stock exchange, or have distributed or are required to distribute to their security holders.
What does 'incorporation by reference' mean in this filing?
It means that the content of previously filed documents (in this case, Form S-8 registration statements) is being included as part of this current filing without needing to be physically re-submitted.
What are the Form S-8 registration statements referenced?
The filing references Form S-8 registration statements with numbers 333-203040 and 3, which are typically used for the registration of securities to be offered to employees under employee benefit plans.
Where is Ascendis Pharma A/S headquartered?
Ascendis Pharma A/S is headquartered in Hellerup, Denmark.
What is the standard industrial classification for Ascendis Pharma A/S?
The standard industrial classification for Ascendis Pharma A/S is Pharmaceutical Preparations [2834].
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 15.7 · Accepted 2025-08-13 16:01:12
Key Financial Figures
- $195.98 — y and has an exercise price equal to US $195.98 per share, the closing price of the Ame
Filing Documents
- d936440d6k.htm (6-K) — 13KB
- d936440dex11.htm (EX-1.1) — 1197KB
- g936440dsp174.jpg (GRAPHIC) — 3KB
- g936440dsp175.jpg (GRAPHIC) — 3KB
- g936440dsp177.jpg (GRAPHIC) — 3KB
- g936440dsp178.jpg (GRAPHIC) — 3KB
- g936440dsp179.jpg (GRAPHIC) — 3KB
- g936440dsp180.jpg (GRAPHIC) — 5KB
- g936440dsp_24a.jpg (GRAPHIC) — 4KB
- g936440dsp_25a.jpg (GRAPHIC) — 8KB
- g936440dsp_25b.jpg (GRAPHIC) — 3KB
- g936440dsp_26a.jpg (GRAPHIC) — 6KB
- g936440dsp_33a.jpg (GRAPHIC) — 4KB
- g936440dsp_33b.jpg (GRAPHIC) — 8KB
- g936440dsp_34a.jpg (GRAPHIC) — 3KB
- g936440dsp_34b.jpg (GRAPHIC) — 6KB
- g936440page43.jpg (GRAPHIC) — 4KB
- g936440page44a.jpg (GRAPHIC) — 8KB
- g936440page44b.jpg (GRAPHIC) — 3KB
- g936440page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-179800.txt ( ) — 1331KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: August 13, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer